Pelage Pharmaceuticals, a clinical-stage regenerative medicine company pioneering a new generation of treatments for hair loss, announced today that the company has closed a $16.75 million Series A financing led by GV with participation from Main Street Advisors, Visionary Ventures and YK BioVentures, to advance a first-in-class treatment for androgenetic alopecia or pattern baldness, and other types of alopecia including chemotherapy-induced hair loss.

"Our scientific co-founders have uncovered a unique biological mechanism with the potential to reactivate hair growth in people with alopecia," said Daniel Gil, Ph.D., Chief Executive Officer, Pelage Pharmaceuticals.

"We are pleased to announce that we have completed a first-in-human Phase 1 clinical trial that demonstrated seven days of topical dosing with PP405 was safe and well-tolerated, and showed statistically significant activation of hair follicle stem cells. With the support of GV, Main Street Advisors and other top-tier investors, we expect to advance our lead program to a Phase 2a clinical trial in the second half of this year."

탈모는 전세계적 중년 남자들의 고민이다. 요즘엔 남자 뿐만 아니라 여성들도 탈모에 빠진다.

미국 LA에 본사를 둔 탈모 치료제 개발업체 펠라지  파마슈티컬스(Pelage Pharmaceuticals)는 약  1,700만 달러 시리즈 A 투자를 유치했다고 밝혔다.  GV, 메인 스트리트(Main Street Advisors) 어드바이저, 비전리 벤처스(Visionary Ventures), YK 바이오벤처스(YK BioVentures) 등이 투자에 참여했다.

투자가 이뤄지면 펠라지는 남성형 탈모증(androgenetic alopecia)이나 원형 탈모증(pattern baldness), 화학 요법으로 인한 탈모(chemotherapy-induced hair loss)를 포함한 기타 유형 탈모증에 대한 치료제 개발에 집중할 계획이다.